uracil has been researched along with Insulin Resistance in 14 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of the study was to evaluate whether dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin (ALO) alone or in combination with pioglitazone (PIO) improves β-cell function along with insulin resistance (IR) in metformin (MET) treated obese women with PCOS with persistent IR." | 9.24 | Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS. ( Goricar, K; Janez, A; Jensterle, M, 2017) |
| "Trelagliptin inhibits the enzyme dipeptidyl-4 (DPP-4) to treat type 2 diabetes and it may possess the potential to improve insulin resistance." | 7.96 | Trelagliptin succinate: DPP-4 inhibitor to improve insulin resistance in adipocytes. ( Kang, W; Liu, Z; Wang, J; Wei, J; Xing, M; Xu, L; Xu, X, 2020) |
| " In this study, we evaluated the efficacy of alogliptin (DPP-4 inhibitor) on hippocampal insulin resistance and associated AD complications." | 7.96 | Alogliptin reversed hippocampal insulin resistance in an amyloid-beta fibrils induced animal model of Alzheimer's disease. ( Akhtar, M; Akhter, M; Kaundal, M; Najmi, AK; Panda, BP; Parvez, S; Rahman, SO; Salman, M; Shrivastava, A, 2020) |
| "The results indicate that alogliptin improves stress-induced prothrombotic state and insulin resistance; suggesting that alogliptin could have beneficial therapeutic effects against cardiovascular complications in diabetic patients under stress." | 7.83 | Dipeptidyl peptidase- IV inhibitor alogliptin improves stress-induced insulin resistance and prothrombotic state in a murine model. ( Cheng, XW; Hao, CN; Hayashi, M; Kikuchi, R; Matsushita, T; Murohara, T; Nakamura, S; Nakayama, T; Takeshita, K; Uchida, Y; Wu, H; Yamamoto, K; Yisireyili, M, 2016) |
| " The aim of the study was to evaluate whether dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin (ALO) alone or in combination with pioglitazone (PIO) improves β-cell function along with insulin resistance (IR) in metformin (MET) treated obese women with PCOS with persistent IR." | 5.24 | Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS. ( Goricar, K; Janez, A; Jensterle, M, 2017) |
| "Hydrogen-rich water has a significant protective effect on OGD/R-causing HT22 cell injury, and the mechanism may be related to the inhibition of autophagy." | 4.40 | Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023) |
| "Trelagliptin inhibits the enzyme dipeptidyl-4 (DPP-4) to treat type 2 diabetes and it may possess the potential to improve insulin resistance." | 3.96 | Trelagliptin succinate: DPP-4 inhibitor to improve insulin resistance in adipocytes. ( Kang, W; Liu, Z; Wang, J; Wei, J; Xing, M; Xu, L; Xu, X, 2020) |
| " In this study, we evaluated the efficacy of alogliptin (DPP-4 inhibitor) on hippocampal insulin resistance and associated AD complications." | 3.96 | Alogliptin reversed hippocampal insulin resistance in an amyloid-beta fibrils induced animal model of Alzheimer's disease. ( Akhtar, M; Akhter, M; Kaundal, M; Najmi, AK; Panda, BP; Parvez, S; Rahman, SO; Salman, M; Shrivastava, A, 2020) |
| "The results indicate that alogliptin improves stress-induced prothrombotic state and insulin resistance; suggesting that alogliptin could have beneficial therapeutic effects against cardiovascular complications in diabetic patients under stress." | 3.83 | Dipeptidyl peptidase- IV inhibitor alogliptin improves stress-induced insulin resistance and prothrombotic state in a murine model. ( Cheng, XW; Hao, CN; Hayashi, M; Kikuchi, R; Matsushita, T; Murohara, T; Nakamura, S; Nakayama, T; Takeshita, K; Uchida, Y; Wu, H; Yamamoto, K; Yisireyili, M, 2016) |
| "Ecological evidence suggests that niacin (nicotinamide and nicotinic acid) fortification may be involved in the increased prevalence of obesity and type 2 diabetes, both of which are associated with insulin resistance and epigenetic changes." | 3.79 | Nicotinamide supplementation induces detrimental metabolic and epigenetic changes in developing rats. ( Cao, JM; Cao, Y; Gong, XJ; Guo, J; Guo, M; Li, D; Lun, YZ; Luo, N; Sun, WP; Tian, YJ; Zhou, SS, 2013) |
| "Treatment naïve subjects with type 2 diabetes received 12." | 2.80 | Alogliptin: a new dipeptidyl peptidase-4 inhibitor with potential anti-atherogenic properties. ( Hirate, M; Kaneoka, N; Kutoh, E, 2015) |
| "Pioglitazone is a potent insulin sensitizer, improves pancreatic beta cell function and has been shown in several outcome trials to lower the risk of atherosclerotic and cardiovascular events." | 2.46 | Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment. ( Cersosimo, E; DeFronzo, RA; Triplitt, C, 2010) |
| " Absolute oral bioavailability of alogliptin in rats, dogs, and monkeys was 45%, 86%, and 72% to 88%, respectively." | 1.35 | Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. ( Asakawa, T; Christopher, RJ; Kassel, DB; Lee, B; Shi, L; Takeuchi, K, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 10 (71.43) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Z | 1 |
| Xu, L | 1 |
| Xing, M | 1 |
| Xu, X | 2 |
| Wei, J | 1 |
| Wang, J | 1 |
| Kang, W | 1 |
| Rahman, SO | 1 |
| Kaundal, M | 1 |
| Salman, M | 1 |
| Shrivastava, A | 1 |
| Parvez, S | 1 |
| Panda, BP | 1 |
| Akhter, M | 1 |
| Akhtar, M | 1 |
| Najmi, AK | 1 |
| Jensterle, M | 1 |
| Goricar, K | 1 |
| Janez, A | 1 |
| Huang, JF | 1 |
| Huang, CF | 1 |
| Yeh, ML | 1 |
| Dai, CY | 1 |
| Hsieh, MH | 1 |
| Yang, JF | 1 |
| Huang, CI | 1 |
| Lin, YH | 1 |
| Liang, PC | 1 |
| Lin, ZY | 1 |
| Chen, SC | 1 |
| Yu, ML | 1 |
| Chuang, WL | 1 |
| Li, D | 1 |
| Tian, YJ | 1 |
| Guo, J | 1 |
| Sun, WP | 1 |
| Lun, YZ | 1 |
| Guo, M | 1 |
| Luo, N | 1 |
| Cao, Y | 1 |
| Cao, JM | 1 |
| Gong, XJ | 1 |
| Zhou, SS | 1 |
| Takebayashi, K | 1 |
| Sakurai, S | 1 |
| Suzuki, T | 1 |
| Hori, K | 1 |
| Terasawa, T | 1 |
| Naruse, R | 1 |
| Hara, K | 1 |
| Suetsugu, M | 1 |
| Tsuchiya, T | 1 |
| Aoki, H | 1 |
| Hamasaki, T | 1 |
| Shuutou, H | 1 |
| Inukai, T | 1 |
| Kutoh, E | 2 |
| Kaneoka, N | 1 |
| Hirate, M | 1 |
| Yisireyili, M | 1 |
| Takeshita, K | 1 |
| Hayashi, M | 1 |
| Wu, H | 1 |
| Uchida, Y | 1 |
| Yamamoto, K | 2 |
| Kikuchi, R | 1 |
| Hao, CN | 1 |
| Nakayama, T | 1 |
| Cheng, XW | 1 |
| Matsushita, T | 1 |
| Nakamura, S | 1 |
| Murohara, T | 1 |
| Lee, B | 1 |
| Shi, L | 1 |
| Kassel, DB | 1 |
| Asakawa, T | 1 |
| Takeuchi, K | 1 |
| Christopher, RJ | 1 |
| Triplitt, C | 1 |
| Cersosimo, E | 1 |
| DeFronzo, RA | 1 |
| Kawashima, S | 1 |
| Matsuoka, TA | 1 |
| Kaneto, H | 1 |
| Tochino, Y | 1 |
| Kato, K | 1 |
| Yamamoto, T | 1 |
| Matsuhisa, M | 1 |
| Shimomura, I | 1 |
| Shah, Z | 1 |
| Kampfrath, T | 1 |
| Deiuliis, JA | 1 |
| Zhong, J | 1 |
| Pineda, C | 1 |
| Ying, Z | 1 |
| Lu, B | 1 |
| Moffatt-Bruce, S | 1 |
| Durairaj, R | 1 |
| Sun, Q | 1 |
| Mihai, G | 1 |
| Maiseyeu, A | 1 |
| Rajagopalan, S | 1 |
| Ukai, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetic Patients With Coronary Artery Disease[NCT01604213] | Phase 4 | 60 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for uracil and Insulin Resistance
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.
Topics: Animals; Cardiovascular System; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Th | 2010 |
5 trials available for uracil and Insulin Resistance
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS.
Topics: Adult; Body Mass Index; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitor | 2017 |
Effect of combination therapy with alogliptin and lansoprazole on glycemic control in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Co | 2014 |
Alogliptin: a new dipeptidyl peptidase-4 inhibitor with potential anti-atherogenic properties.
Topics: Adult; Aged; Atherosclerosis; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipep | 2015 |
Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial.
Topics: Adult; Diabetes Mellitus, Type 2; Diet, Diabetic; Diet, Fat-Restricted; Dipeptidyl-Peptidase IV Inhi | 2012 |
8 other studies available for uracil and Insulin Resistance
| Article | Year |
|---|---|
Trelagliptin succinate: DPP-4 inhibitor to improve insulin resistance in adipocytes.
Topics: 3T3-L1 Cells; Adipocytes; Adipokines; Animals; Dipeptidyl-Peptidase IV Inhibitors; Fatty Acids, None | 2020 |
Alogliptin reversed hippocampal insulin resistance in an amyloid-beta fibrils induced animal model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Dipeptidyl-Peptidase IV Inhibitors; Dise | 2020 |
The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combinat | 2017 |
Nicotinamide supplementation induces detrimental metabolic and epigenetic changes in developing rats.
Topics: Animals; Betaine; Choline; CpG Islands; Dietary Supplements; DNA; DNA Damage; DNA Methylation; Epige | 2013 |
Dipeptidyl peptidase- IV inhibitor alogliptin improves stress-induced insulin resistance and prothrombotic state in a murine model.
Topics: Adipose Tissue; Animals; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, | 2016 |
Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
Topics: Administration, Oral; Animals; Biological Availability; Blood Glucose; Dipeptidyl Peptidase 4; Dipep | 2008 |
Effect of alogliptin, pioglitazone and glargine on pancreatic β-cells in diabetic db/db mice.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Blood Glucose; Body Weight; Deoxyguanosine; Dipeptidyl-Peptida | 2011 |
Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Blood Pressure; Cell Movement; Chemotaxis; Dipeptidyl-P | 2011 |